- Home
- CINT vs FDMT Comparison
CINT vs FDMT Comparison
Compare CINT & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CINT | FDMT |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | Brazil | United States |
| Employees | 7858 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.9M | 513.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CINT | FDMT |
|---|---|---|
| Price | $5.46 | $8.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.02 | ★ $32.40 |
| AVG Volume (30 Days) | 90.8K | ★ 674.7K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,000.00 |
| Revenue This Year | $14.06 | $21,227.03 |
| Revenue Next Year | $11.51 | $161.87 |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.98 | $2.24 |
| 52 Week High | $6.71 | $12.34 |
Technical Indicators
Market Signals| Indicator | CINT | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 42.07 |
| Support Level | $5.26 | $8.15 |
| Resistance Level | $5.51 | $8.80 |
| Average True Range (ATR) | 0.24 | 0.55 |
| MACD | 0.05 | -0.12 |
| Stochastic Oscillator | 55.41 | 7.86 |
Price Performance
Historical ComparisonAbout CINT CI&T Inc
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.